Score Pharma, Inc. Market Research Report
Background
Company Overview
Score Pharma, Inc. is a biotechnology company specializing in the development of enhanced antibody therapeutics. Founded in 2018 and headquartered in Huntsville, Alabama, the company leverages its proprietary CoreX technology to improve existing monoclonal antibody (mAb) treatments, aiming to enhance patient responses, particularly in oncology.
Mission and Vision
Score Pharma's mission is to transform existing, clinically validated antibody therapeutics into more potent treatments by enhancing their antibody-dependent cellular cytotoxicity (ADCC) capabilities. The company's vision is to deliver next-generation antibody therapies that significantly improve patient outcomes in cancer treatment.
Primary Area of Focus
The company's primary focus is on oncology, targeting diseases such as non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and HER2-positive breast cancer. By enhancing existing antibody therapies, Score Pharma aims to provide more effective treatment options for these conditions.
Industry Significance
In the biotechnology industry, particularly within the oncology sector, the development of enhanced antibody therapeutics is crucial. By improving the efficacy of existing treatments, companies like Score Pharma contribute to advancing cancer care and addressing unmet medical needs.
Key Strategic Focus
Core Objectives
Score Pharma's strategic objectives include:
- Enhancing Existing Therapies: Utilizing CoreX technology to improve the ADCC response of existing mAb treatments.
- Accelerating Development: Developing enhanced therapeutics to Phase 1 clinical trials and out-licensing them for further development, thereby reducing time-to-market.
Specific Areas of Specialization
The company specializes in:
- ADCC Enhancement: Modifying antibodies to increase their ability to induce immune-mediated destruction of cancer cells.
- Oncology Treatments: Focusing on cancers such as NHL, CLL, and HER2-positive breast cancer.
Key Technologies Utilized
Score Pharma employs its proprietary CoreX technology, which involves the use of cell culture additives to create afucosylated biobetter antibody therapeutics. This process enhances the ADCC response, improving the binding between immune cells and cancer cells targeted by the antibody.
Primary Markets or Conditions Targeted
The company primarily targets the oncology market, focusing on treatments for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and HER2-positive breast cancer.
Financials and Funding
Funding History
Score Pharma has undergone multiple funding rounds, including:
- Seed Funding (July 2024): The company secured a seed funding round led by the Therapeutics Development Fund, with participation from other investors.
Total Funds Raised
The total funds raised by Score Pharma are not publicly disclosed.
Notable Investors
Notable investors include the Therapeutics Development Fund, The Science Inc Accelerator, gBETA Urban League, Pinnacle Atlanta Innovation Accelerator, and gBETA Madison.
Intended Utilization of Capital
The capital raised is intended to support the development of enhanced antibody therapeutics, advance preclinical and clinical trials, and facilitate out-licensing agreements for further development.
Pipeline Development
Key Pipeline Candidates
Score Pharma's pipeline includes:
- Lead Program: A biosuperior anti-HER2 trastuzumab for the treatment of breast cancer.
Stages of Clinical Trials or Product Development
The lead program is in the preclinical stage, with plans to advance to Phase 1 clinical trials.
Target Conditions
The primary target condition is HER2-positive breast cancer.
Relevant Timelines for Anticipated Milestones
Specific timelines for clinical milestones are not publicly disclosed.
Technological Platform and Innovation
Proprietary Technologies
Score Pharma's proprietary CoreX technology enhances the ADCC response of antibodies by modulating core fucosylation during antibody production. This process increases the binding affinity between immune cells and cancer cells, potentially improving therapeutic efficacy.
Significant Scientific Methods
The company employs cell culture additives to achieve afucosylation, a key aspect of its CoreX technology.
AI-Driven Capabilities
There is no publicly available information indicating the use of AI-driven capabilities in Score Pharma's operations.
Leadership Team
Key Executive Profiles
- Bruce Edward Jones, Ph.D. – Founder, President, and CEO
Dr. Jones has over 30 years of experience in the pharmaceutical and biopharmaceutical industry. He has directed drug discovery and disease biology groups at companies like Cephalon and Regeneron. He is the inventor of Score Pharma's proprietary process technology.
- Steven Feder – Co-Founder, Board Member, and Secretary
Mr. Feder has over 30 years of experience as a life sciences executive and attorney. He has a record of early-stage company development and growth, including financings and partnering/M&A. He is skilled in finance, HR, outsourcing, IP strategy, and compliance.
- Martina Molsbergen – Co-Founder and Vice President, Business Development
Ms. Molsbergen has closed over 17 out-licensing deals for genetic modification ADCC enhancement technology, resulting in products generating multi-billion dollar revenue streams.
Leadership Changes
There is no publicly available information regarding recent leadership changes.
